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Abstract The objective of the study was to investigate the
effects of five organic vanadium complexes supplement and
a small dose of insulin injection on V, Fe, Cu, Zn, Mn, Ca,
and K level in the streptozotocin diabetic rat’s kidney during
a 5-week treatment with the tested complexes. In all groups
of animals, metal level in the lyophilized kidney organs was
investigated by means of the proton induced X-ray emission
method. Tissue vanadium level was naturally higher in
vanadium-treated rats. The maximum level of vanadium
was observed in the kidney (xmean ¼ 16:6 μg=gÞ. The influ-
ence of vanadium administration on other metal level in rat’s
tissue was also investigated. Spectacular influence of vana-
dium action was observed on copper and zinc level in
examined tissue.
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Introduction
Diabetes is one of the most frequent diseases in developed
countries. Every year, the incidence of this disease signifi-
cantly increases. The prediction for 2030 is more than 500
million persons with diabetes, especially type 2, worldwide
[1]. This phenomenon results primarily from the lifestyle
changes: decrease of physical effort and, above all, excess of
calories from badly balanced diet, especially from fast food
[2–6]. In type 1 diabetes, auto-aggression destroys β-cells
and leads to insulin production atrophy. The mechanism of
this type of disease is observed in a lot of laboratories [7, 8].
Insulin production in the pancreas is a multistage process
sensitive to glucose level. Also, proper level of micro-
elements, especially zinc [9, 10] plays an important role in
secretion of this hormone. Type 1 diabetes in an animal
model can be provoked by a streptozotocin (STZ) injection
which destroys β-cells within 2–3 days [11–13]. During this
time, the glucose level can increase to more than 30 mmol/l,
with all symptoms of not treated type 1 diabetes. Since the
1980s, vanadium compounds have been tested as potential
therapeutic agents in type 1 [14–16] and type 2 [17–20]
diabetes. Some organic and inorganic vanadium compounds
have presented interesting influence on biochemical markers
like decrease of glucose level and improvement of other
biochemical parameters. Negative effects of vanadium treat-
ment on intestinal tract, such as diarrhea, vomiting etc., have
been frequently reported [21, 22]. This was associated with
high doses of administered vanadium compounds. Now-
adays, scientific attempts concentrate on the decrease of
negative effects and increase of therapeutic activity in
both diabetes models. In particular, vanadium complexes
with organic ligands present interesting proprieties
[23–27] and usually higher bioavailability [28]. Some
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of them have already been tested on patients in clinical
trials [26, 27]. Trace elements supplementation in case
of vanadium can influence not only biochemical param-
eters but also other element level in organs [29, 30].
This work focuses on a recondite effect of vanadium
treatment on other levels of elements in the kidney of
diabetic STZ rats.
Material and Methods
Animals and Vanadium Administration
Male Wistar rats weighing between 220 and 250 g were
divided into seven groups of six animals in each group.
During all time, animals had free access to water and
feed. After 3 days from the beginning of the experi-
ment, 55 mg of streptozotocine in citric buffer
(0.1 mol/l) solution per 1 kg of body mass was injected
into the caudal in all groups of animals. Three days
subsequent to the injections, the level of glucose was
measured and the glucose level measured in animal
blood was higher than 17 mmol/l. After the measure-
ment, the rats were separated into the following tested
groups: diabetic control rats (D), diabetic rats with
insulin (Di), five groups of diabetic rats with insulin
and tested complexes (Di1–5). The tested complexes of
vanadium were administered daily in dose of 50 μmol/kg
and 1 U/kg of insulin was injected subcutaneously. Five
weeks after beginning of first insulin injection and va-
nadium complexes administration, animal were anesthe-
tized (thiopental, 50 mg/kg) and then the kidneys were
collected. For kidney collection, stainless steel
chirurgical scissors and tweezers in all groups of ani-
mals were used. Kidneys were directly inserted to plas-
tic tubes and kept frozen in −20 °C until the time of
analysis. Experiment got the agreement from Local Eth-
ic Commission in Krakow ZI/UJ/185/2003.
Fig. 1 Vanadium level in rat’s
kidney in different groups of
animals (D diabetic, Di diabetic
with insulin, Di1 diabetic with
insulin and vanadium complex
1, Di2 diabetic with insulin and
vanadium complex 2, Di3
diabetic with insulin and
vanadium complex 3, Di4
diabetic with insulin and
vanadium complex 4, Di5
diabetic with insulin and
vanadium complex 5, C
control)
Table 1 Differences statistically significant for vanadium level be-
tween animal groups: D diabetic, Di diabetic with insulin, Di1 diabetic
with insulin and vanadium complex 1, Di2 diabetic with insulin and
vanadium complex 2, Di3 diabetic with insulin and vanadium complex
3, Di4 diabetic with insulin and vanadium complex 4, Di5 diabetic
with insulin and vanadium complex 5, C control (***p<0.001)
D Di Di1 Di2 Di3 Di4 Di5 C
D –
Di –
Di1 *** *** –
Di2 *** *** –
Di3 *** *** –
Di4 *** *** –
Di5 *** *** –
C *** *** *** *** *** –
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Used complexes
1. Na[VO(O2)2(2,2′-bpy)] · 8 H2O (molar mass =
453.94 g/mol)
2. Na[VO(O2)2(1,10′-phen)] · 5 H2O (molar mass=
423.94 g/mol)
3. Na[VO(O2)2(4,4′-Me-2,2′-bpy)] · 8 H2O (molar mass=
481.94 g/mol)
4. [VO(SO4)(1,10 ′-phen)] · 2 H2O (molar mass =
363 g/mol)
5. [VO(SO4)(2,2′-bpy)] · H2O (molar mass=321 g/mol)
where synthesized by the method described in the literature
[31–33].
Used abbreviation: bpy, bypiridyne; phen, phenanthroline,
and Me, methyl. Their purity was confirmed by elemental
analysis and infrared spectroscopy.
Kidney Tissue Preparation
Frozen kidney tissue was transferred directly to lyophi-
lizing cabinet and lyophilized using ABCONO
FREEZONE 4,5 in temperature from −40 to −53 °C,
and under pressure of 14–1 Pa. Then, the lyophilized
kidney tissue was homogenated in agate mortar and
pressed into pellets, about 1 mm thick and 10 mm in
diameter, by pressure of 15 MPa in home-made appara-
tus. Such pellets were placed on Scotch tape and at-
tached to an aluminum frame.
Proton-induced X-ray Emission Analysis
A 2 MeV proton beam from the Van de Graaff accelerator
was directed at the sample for a multitrace (K, Ca, Mn, Fe,
Cu, Zn, and V) element analysis. Each sample was mea-
sured twice. Standard Reference Material 1577b Bovine
Liver was also used. All the collected spectra were analyzed
using GupixWin ver. 2.0 software. The statistical calcula-
tions were performed using Statistica 7.1 program. Differ-
ences between the studied rat groups were estimated using a
Fig. 2 Iron level in rat’s kidney
in different groups of animals
(D diabetic, Di diabetic with
insulin, Di1 diabetic with
insulin and vanadium complex
1, Di2 diabetic with insulin and
vanadium complex 2, Di3
diabetic with insulin and
vanadium complex 3, Di4
diabetic with insulin and
vanadium complex 4, Di5
diabetic with insulin and
vanadium complex 5, C
control)
Table 2 Differences statistically significant for iron level between
animal groups: D diabetic, Di diabetic with insulin, Di1 diabetic with
insulin and vanadium complex 1, Di2 diabetic with insulin and vana-
dium complex 2, Di3 diabetic with insulin and vanadium complex 3,
Di4 diabetic with insulin and vanadium complex 4, Di5 diabetic with
insulin and vanadium complex 5, C control (*p<0.05)
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nonparametric Kruskal–Wallis test. Full methodology was
described in Acta Pol Pharm (2013) 70: 71–77.
Results
Vanadium In all vanadium-treated animal groups, the
level of this element was significantly (p<0.001) higher
in comparison to not treated groups (Fig. 1 and Table 1).
No differences were observed between the vanadium
organoligands used. Similar absence of differences was
observed in animal groups not treated with vanadium.
Iron Iron level in the kidney presented only one signif-
icant difference between the two tested vanadium
organoligands—Di1 vs. Di5 (Fig. 2 and Table 2). The
obtained results indicate higher level of this metal in
diabetic animals as compared to the control group.
Presumably, more numerous groups would have shown
significant differences.
Copper The copper level in the kidney is evidently
associated with diabetes. In diabetic animals not treated
with vanadium, the copper level was significantly
higher in comparison to vanadium-treated rats and con-
trol groups. Vanadium treatment has reduced the level
of this metal to a value close to the control group
(Fig. 3 and Table 3). Vanadium compound used in the
Di1 group had a lesser influence on copper decrease in
diabetic animals.
Zinc Vanadium treatment had very high influence on zinc
level in the kidney (Fig. 4 and Table 4). The obtained results
have shown the decrease of zinc level in all vanadium-
treated groups (p<0.01). On the other hand, diabetes in-






























Fig. 3 Copper level in rat’s
kidney in different groups of
animals (D diabetic, Di diabetic
with insulin, Di1 diabetic with
insulin and vanadium complex
1, Di2 diabetic with insulin and
vanadium complex 2, Di3
diabetic with insulin and
vanadium complex 3, Di4
diabetic with insulin and
vanadium complex 4, Di5
diabetic with insulin and
vanadium complex 5, C
control)
Table 3 Differences statistically significant for copper level between
animal groups: D diabetic, Di diabetic with insulin, Di1 diabetic with
insulin and vanadium complex 1, Di2 diabetic with insulin and vana-
dium complex 2, Di3 diabetic with insulin and vanadium complex 3,
Di4 diabetic with insulin and vanadium complex 4, Di5 diabetic with
insulin and vanadium complex 5, C control (*p<0.05, **p<0.01, ***p
<0.001)
D Di Di1 Di2 Di3 Di4 Di5 C
D –
Di –
Di1 * * –
Di2 ** ** –
Di3 ** ** –
Di4 ** ** –
Di5 ** ** –
C *** *** * –
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Manganese The manganese level in the kidney is associated
with vanadium treatment. In all groups with vanadium ad-
ministration, the level of manganese was higher in compar-
ison to diabetic one and to control group (Fig. 5 and
Table 5). No differences were observed between the vana-
dium organoligands used.
Calcium The calcium level in the kidney seems to be
not associated with vanadium treatment. The increase of
the calcium level in the kidney in the diabetic animals
was statistically significant in comparison to the control
group (Fig. 6 and Table 6). However, in all diabetic
groups, both with and without vanadium treatment, the
calcium level was similar and higher than in case of the
control group.
Potassium The potassium level was highest in diabetic
and diabetic with insulin groups. Lowest level of potas-
sium was observed in group treated with complex 4
(Fig. 7 and Table 7). The differences were statistically
significant. Also, significant differences associated with
type of vanadium compound were observed between
groups Di1 and Di4.
Discussion
Diabetes and especially not treated diabetes deteriorating
kidney function [34–36]. An increased glucose level in the
blood during diabetes negatively influences the efficiency of
this organ. An increase of thirst and urine production [37] in
not treated diabetes is visible. A high glucose level and
hypertension have principal role in diabetic nephropathy.
The dysfunction of the kidney drastically changes the total
organism homeostasis and can cause death from renal fail-
ure. The most important role of the kidney is water and
mineral recovery and elimination of nitrogen metabolites.




























Fig. 4 Zinc level in rat’s
kidney in different groups of
animals (D diabetic, Di diabetic
with insulin, Di1 diabetic with
insulin and vanadium complex
1, Di2 diabetic with insulin and
vanadium complex 2, Di3
diabetic with insulin and
vanadium complex 3, Di4
diabetic with insulin and
vanadium complex 4, Di5
diabetic with insulin and
vanadium complex 5, C
control)
Table 4 Differences statistically significant for zinc level between ani-
mal groups:D diabetic,Di diabetic with insulin,Di1 diabetic with insulin
and vanadium complex 1, Di2 diabetic with insulin and vanadium com-
plex 2, Di3 diabetic with insulin and vanadium complex 3, Di4 diabetic
with insulin and vanadium complex 4, Di5 diabetic with insulin and
vanadium complex 5, C control (*p<0.05, **p<0.01, ***p<0.001)
D Di Di1 Di2 Di3 Di4 Di5 C
D –
Di –
Di1 * ** –
Di2 * ** –
Di3 * ** –
Di4 ** *** –
Di5 ** *** –
C * * * * * * –
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elements, which can increase the organism dysfunction [38].
Vanadium administration in rats evidently increases the
level of this element in the kidney more than 10 times in
comparison to animals not treated with vanadium. This
observation is similar for other studies in which the accu-
mulation of vanadium in organs was observed after the
treatment with ions of this metal [39–41]. The vanadium
absorption from the gastrointestinal tract is associated with
chemical structure of used compound. In case of used com-
plexes in the present experiment, only two complexes (1 and
5) had pharmacokinetic study [28]. Bioavailability of these
complexes was 27–30 % and was higher in comparison to
vanadyl sulfate was −18 %. For other complexes, pharma-
cokinetics study was not made for this time. An interesting
observation was noted for zinc and copper levels. STZ-
induced diabetes statistically increases both elements levels.
Similar effects were reported by Sivikaya et al. [42] for not
treated STZ diabetes in the kidney. The increase of both
elements can give information about an important role of
these metals in diabetes development. It is probably associ-
ated with an increased uptake of zinc and copper in the
kidney from blood during urine production. Treatment with
vanadium in our work and with zinc in Sivikaya et al. work
decreased levels of both elements in the kidney tissue.
Vanadium complexes administered in a dose of
20 mg/kg/day (about 5–6 mg of pure vanadium depending
of compound per kilogram per day) had higher influence on
the zinc and copper level in the kidney than zinc in Sivikaya
et al. work. As for copper, the level in all vanadium-treated
groups was similar to the control group. The diabetic groups
which were not treated with vanadium sometimes showed
higher levels of copper than the control group. In the
work of Sivikaya et al., zinc level in the kidney in
zinc-treated animals was higher but zinc treatment can
influence the total zinc level in the kidney. The question
is if this increase of zinc and copper in the kidney of
diabetic, not treated animal is associated with higher



























Fig. 5 Manganese level in rat’s
kidney in different groups of
animals (D diabetic, Di diabetic
with insulin, Di1 diabetic with
insulin and vanadium complex
1, Di2 diabetic with insulin and
vanadium complex 2, Di3
diabetic with insulin and
vanadium complex 3, Di4
diabetic with insulin and
vanadium complex 4, Di5
diabetic with insulin and
vanadium complex 5, C
control)
Table 5 Differences statistically significant for manganese level be-
tween animal groups: D diabetic, Di diabetic with insulin, Di1 diabetic
with insulin and vanadium complex 1, Di2 diabetic with insulin and
vanadium complex 2, Di3 diabetic with insulin and vanadium complex
3, Di4 diabetic with insulin and vanadium complex 4, Di5 diabetic
with insulin and vanadium complex 5, C control (*p<0.05, **p<0.01)
D Di Di1 Di2 Di3 Di4 Di5 C
D –
Di –
Di1 * * –
Di2 * * –
Di3 * * –
Di4 ** ** –
Di5 ** ** –
C * * * * –
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tissues. The increase of zinc and copper in those cases
could possibly be explained by the fact that the accu-
mulation of these elements in the kidney occurs to
protect the organism from an important element loss.
Zinc has an especially important role in insulin produc-
tion and in protecting the organism against free radicals.
There may also be a different explanation of the zinc
and copper increase in the vanadium-treated animals.
Streptozotocin destroys pancreatic island cells and after
STZ administration zinc is eliminated also from the
pancreas.
As for the calcium level in the kidney, an increase of this
element in all diabetic groups was observed. Adding vana-
dium compounds did not affect the level of calcium in the
tested tissue in all groups of animals (both treated and not
treated). It is, therefore, possible to form a hypothesis that
the calcium level in the kidney is closely connected with
diabetes, both treated and not treated with vanadium com-
pounds. The observed results are similar to the ones in the
work of Dogru Pekine et al. [43]. A different effect was
observed in Sivikaya et al. [42] where zinc treatment in STZ
diabetic rats caused a decrease of the calcium level in the
kidney of the animals.
The manganese level was statistically higher in all the
vanadium-treated groups in comparison to the control and
diabetic vanadium not-treated groups. It is difficult to com-
pare the obtained results with other works because so far the
vanadium and manganese interaction was not tested in the
STZ diabetic model in the kidney. In the work of Sakai et al.
[44], an interaction between zinc and manganese in diabetic
animals showed a similar increase of manganese in the
kidney in zinc-treated animals.
The iron level in the kidney was the most variable ele-
ment. Diabetes presented a trend in its increase in compar-
ison to the control group but it was not significant.
Vanadium treatment, especially the type of used complex,
resulted in differences between all the five tested vanadium
organoligands. Three of the tested complexes—1, 2, and
3—statistically increase the iron level in the kidney in


























Fig. 6 Calcium level in rat’s
kidney in different groups of
animals (D diabetic, Di diabetic
with insulin, Di1 diabetic with
insulin and vanadium complex
1, Di2 diabetic with insulin
and vanadium complex 2, Di3
diabetic with insulin
and vanadium complex 3,
Di4 diabetic with insulin and
vanadium complex 4,
Di5 diabetic with insulin
and vanadium complex 5,
C control)
Table 6 Differences statistically significant for calcium level between
animal groups: D diabetic, Di diabetic with insulin, Di1 diabetic with
insulin and vanadium complex 1, Di2 diabetic with insulin and vana-
dium complex 2, Di3 diabetic with insulin and vanadium complex 3,
Di4 diabetic with insulin and vanadium complex 4, Di5 diabetic with
insulin and vanadium complex 5, C control (*p<0.05)








C * * * * * * –
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complex of vanadium five (Di5) decreased the iron level in
the kidney in diabetic vanadium-treated animals in compar-
ison to the control group. Differences between vanadium
compounds and their influence on the iron level in the
kidney were observed by Thompson et al. [45], but they
preformed an experiment with healthy animals. These dif-
ferences may be associated with an oxidation state or ab-
sorption from the intestinal system.
All vanadium complexes used in the experiment were
with organoligands. The changes observed in the level of the
other elements were similar for the tested complexes in all
cases except for the iron level. It can suggest that the type of
organic ligand used has minimal influence on the measured
metal level and the observed results are associated only with
the vanadium action and its oxidation state. Probably, bio-
availabilities of all tested complexes are very similar and
animals had the some vanadium intake by examined organ.
In case of iron, the situation is more complicated. Evidently,
influence of used organoligands can be observed. It is espe-
cially exposed for complexes 1, 2, and 3 versus complex 5.
This can suggests that the iron level can be correlated with
an oxidation state of vanadium. In complexes 1–3, it is the
vanadium (IV) oxidation state and for 4 and 5, it is vanadi-
um (V) oxidation state. Analyzed interaction between iron
level in kidney and vanadium treatment are few and require
further research to verify the presented hypothesis. The
obtained results also suggest that there are changes in metal
levels in the investigated organ (the kidney) associated with
diabetes. Metal supplementation can probably be useful in
the treatment of this disease but further studies are required
to confirm these findings. Another problem is contamination
of used stainless steel chirurgical scissors and tweezers for
iron and manganese level in kidney. During organ collec-
tion, the same procedure was used. Probability of contami-
nation of the samples of these metals is very similar. Large
differences of metals level in the analyzed samples was not
observed within the groups and this suggesting about of























Fig. 7 Potassium level in rat’s
kidney in different groups of
animals (D diabetic, Di diabetic
with insulin, Di1 diabetic with
insulin and vanadium complex
1, Di2 diabetic with insulin and
vanadium complex 2, Di3
diabetic with insulin and
vanadium complex 3, Di4
diabetic with insulin and
vanadium complex 4, Di5
diabetic with insulin and
vanadium complex 5, C
control)
Table 7 Differences statistically significant for potassium level be-
tween animal groups: D diabetic, Di diabetic with insulin, Di1 diabetic
with insulin and vanadium complex 1, Di2 diabetic with insulin and
vanadium complex 2, Di3 diabetic with insulin and vanadium complex
3, Di4 diabetic with insulin and vanadium complex 4, Di5 diabetic
with insulin and vanadium complex 5, C control (*p<0.05)
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326 Krośniak et al.
Acknowledgments We would like to express our gratitude to Prof.
Janine Brès for her advice and to Krzysztof Ryt for the samples of
liophilization. This work has been partially supported by an individual
grant WL/403/P/F
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and








Accessed 14 August 2012
4. http://diabetes.niddk.nih.gov/dm/pubs/amIatrisktype2AI/
amerindrisk.pdf. Accessed 14 Aug 2012
5. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C (2007)
Epidemiology of type 2 diabetes: Indian scenario. Indian J Med
Res 125:217–230
6. Odegaard AO, Koh WP, Yuan JM, Gross MD, Pereira MA (2012)
Western-style fast food intake and cardiometabolic risk in an
eastern country. Circulation 126:182–188
7. Hänninen A, Nurmela R, Maksimow M, Heino J, Jalkanen S,
Kurts C (2007) Islet beta-cell-specific T cells can use different
homing mechanisms to infiltrate and destroy pancreatic islets.
Am J Pathol 170:240–250, Erratum in: Am J Pathol. 2008;
172:1153
8. Von Herrath M, Rottembourg D, Bresson D (2006) Progress in the
development of immune-based therapies for type 1 diabetes
mellitus. BioDrugs 20:341–350
9. Bosco MD, Mohanasundaram DM, Drogemuller CJ, Lang CJ,
Zalewski PD, Coates PT (2010) Zinc and zinc transporter regula-
tion in pancreatic islets and the potential role of zinc in islet
transplantation. Rev Diabet Stud 7:263–274. doi:10.1900/
RDS.2010.7.263
10. Bideci A, Camurdan MO, Cinaz P, Dursun H, Demirel F (2005)
Serum zinc, insulin-like growth factor-I and insulin-like growth
factor binding protein-3 levels in children with type 1 diabetes
mellitus. J Pediatr Endocrinol Metab 18:1007–1011
11. Yoon JW, Kim CJ, Pak CY, McArthur RG (1987) Effects of
environmental factors on the development of insulin-dependent
diabetes mellitus. Clin Invest Med 10:457–469
12. Lee SH, Park IS (2000) Effects of soybean diet on the beta cells in
the streptozotocin treated rats for induction of diabetes. Diabetes
Res Clin Pract 47:1–13
13. Ozawa Y, Kurihara T, Sasaki M, Ban N, Yuki K, Kubota S,
Tsubota K (2011) Neural degeneration in the retina of the
streptozotocin-induced type 1 diabetes model. Exp Diabetes Res
2011:108328. doi:10.1155/2011/108328
14. Heyliger CE, Tahiliani AG, McNeill JH (1985) Effect of vanadate
on elevated blood glucose and depressed cardiac performance of
diabetic rats. Science 227:1474–1477
15. Iglesias-González T, Sánchez-González C, Montes-Bayón M,
Llopis-González J, Sanz-Medel A (2012) Absorption, transport
and insulin-mimetic properties of bis(maltolato)oxovanadium
(IV) in streptozotocin-induced hyperglycemic rats by integrat-
ed mass spectrometric techniques. Anal Bioanal Chem
402:277–285
16. Ahmadi S, Karimian SM, Sotoudeh M, Bahadori M, Dehghani GA
(2010) Pancreatic islet beta cell protective effect of oral vanadyl
sulphate in streptozotocin-induced diabetic rats, an ultrastructure
study. Pak J Biol Sci 13:1135–1140
17. Thompson KH, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig
C (2009) Vanadium treatment of type 2 diabetes: a view to the
future. J Inorg Biochem 103:554–558
18. Smith DM, Pickering RM, Lewith GT (2008) A systematic review
of vanadium oral supplements for glycaemic control in type 2
diabetes mellitus. QJM 101:351–358
19. Karmaker S, Saha TK, Yoshikawa Y, Sakurai H (2007)
Amelioration of hyperglycemia and metabolic syndromes in type
2 d i abe t i c KKA(y ) mice by po ly (gamma-g lu tamic
acid)oxovanadium(IV) complex. ChemMedChem 2:1607–1612
20. Adachi Y, Yoshikawa Y, Yoshida J, Kodera Y, Katoh A, Takada J,
Sakurai H (2006) Improvement of diabetes, obesity and hypertension
in type 2 diabetic KKAy mice by bis(allixinato)oxovanadium(IV)
complex. Biochem Biophys Res Commun 345:945–950
21. Llobet JM, Domingo JL (1984) Acute toxicity of vanadium com-
pounds in rats and mice. Toxicol Lett 23:227–231
22. Boulassel B, Sadeg N, Roussel O, Perrin M, Belhadj-Tahar H
(2011) Fatal poisoning by vanadium. Forensic Sci Int 206:e79–e81
23. Li M, Smee JJ, Ding W, Crans DC (2009) Anti-diabetic effects of
sodium 4-amino-2,6-dipicolinatodioxovanadium(V) dihydrate in
streptozotocin-induced diabetic rats. J Inorg Biochem 103:585–589
24. Reul BA, Amin SS, Buchet JP, Ongemba LN, Crans DC, Brichard
SM (1999) Effects of vanadium complexes with organic ligands on
glucose metabolism: a comparison study in diabetic rats. Br J
Pharmacol 126:467–477
25. Wei Y, Zhang C, Zhao P, Yang X, Wang K (2011) A new salicylic
acid-derivatized kojic acid vanadyl complex: synthesis, character-
ization and anti-diabetic therapeutic potential. J Inorg Biochem
105:1081–1085
26. Thompson KH, Orvig C (2006) Vanadium in diabetes: 100 years
from phase 0 to phase I. J Inorg Biochem 100:1925–1935
27. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker
EJ, Jiang ZY, Willsky GR, Kahn CR (2000) Metabolic effects of
vanadyl sulfate in humans with non-insulin-dependent diabetes
mellitus: in vivo and in vitro studies. Metabolism 49:400–410
28. KrosniakM, Azay-Milhau J, GrybośR, , Cros G, Gatacceca F, Brés J
(2008) Vanadium pharmacokinetics and bioavailability of two vana-
dium bipyridine complexes, with reference to vanadyl sulfate, after
oral administration to streptozotocin-induced diabetic rats. Metal ions
in biology and medicine Vol. 10. Libbey: Paris, 769–775
29. Sánchez C, Torres M, Bermúdez-Peña MC, Aranda P, Montes-
Bayón M, Sanz-Medel A, Llopis J (2011) Bioavailability, tissue
distribution and hypoglycaemic effect of vanadium in magnesium-
deficient rats. Magnes Res 24:196–208
30. Edel AL, Kopilas M, Clark TA, Aguilar F, Ganguly PK, Heyliger
CE, Pierce GN (2006) Short-term bioaccumulation of vanadium
when ingested with a tea decoction in streptozotocin-induced
diabetic rats. Metabolism 55:263–270
31. Krośniak M, Zachwieja Z, Filipek B, Zygmunt M, Gryboś R
(2001) Effect of oxovanadium(IV) complexes on nondiabetic and
streptozotocin-diabetic rats. Arch Pharm Pharm Med Chem
334:373–374
32. Przybylski W, Gryboś R, Rehder D, Ebel M, GrzywaM, Łasocha W,
Lewiński K, Szklarzewicz JT (2009) Role of the alkali metal ion and
hydrogen bonds in M[VO(O2)2bpy] nH2O (M = Li
+, Na+, K+ and
Rb+) and Cs[VO(O2)2bpy] H2O2 complexes: the X-ray crystal struc-
tures and spectroscopic properties. Polyhedron 28:1429–1436
33. Krośniak M, Gawlik M, Gryboś R (2009) Effect of vanadium
complexes and insulin administered simultaneously for oxidative
stress in STZ diabetic rats. Bull Vet Inst Pulawy 53:535–540
Influence of vanadium–organic ligands treatment 327
34. Karihaloo A (2012) Anti-fibrosis therapy and diabetic nephropa-
thy. Curr Diab Rep 12:414–422
35. Pyram R, Kansara A, Banerji MA, Loney-Hutchinson L (2012)
Chronic kidney disease and diabetes. Maturitas 71:94–103
36. Bakris GL (2011) Recognition, pathogenesis, and treatment of
different stages of nephropathy in patients with type 2 diabetes
mellitus. Mayo Clin Proc 86:444–456
37. Samarasinghe S, Vokes T (2006) Diabetes insipidus. Expert Rev
Anticancer Ther Suppl 9:S63–S74
38. Ozcelik D, Tuncdemir M, Ozturk M, Uzun H (2011) Evaluation of
trace elements and oxidative stress levels in the liver and kidney of
streptozotocin-induced experimental diabetic rat model. Gen Physiol
Biophys 30:356–363
39. Zhang SQ, Zhong XY, Chen GH, Lu WL, Zhang Q (2008)
The anti-diabetic effects and pharmacokinetic profiles of
bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
J Pharm Pharmacol 60:99–105
40. Zhang SQ, Zhong XY, Lu WL, Zheng L, Zhang X, Sun F, Fu GY,
Zhang Q (2005) Pharmacodynamics and pharmacokinetics of the
insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and
diabetic rats. J Inorg Biochem 99:1064–1075
41. Kowalska J, Krośniak M, Gryboś R, Kwiatek WM (2009)
Investigation of trace element concentration in diabetic rat's tis-
sues. Acta Phys Polon A 115:556–560
42. Sivrikaya A, Bicer M, Akil M, Baltaci AK, Mogulkoc R (2012)
Effects of zinc supplementation on the element distribution in
kidney tissue of diabetic rats subjected to acute swimming. Biol
Trace Elem Res 147:195–199
43. Dogru Pekiner B, Daş Evcimen N, Ulusu NN, Bali M, Karasu C
(2003) Effects of vitamin E on microsomal Ca(2+)-ATPase activity
and calcium levels in streptozotocin-induced diabetic rat kidney.
Cell Biochem Funct 21:177–182
44. Sakai T, Miki F, Wariishi M, Yamamoto S (2004)
Comparative study of zinc, copper, manganese, and iron
concentrations in organs of zinc-deficient rats and rats treated
neonatally with L-monosodium glutamate. Biol Trace Elem
Res 97:163–182
45. Thompson KH, Tsukada Y, Xu Z, Battell M, McNeill JH,
Orvig C (2002) Influence of chelation and oxidation state on
vanadium bioavailability, and their effects on tissue concen-
trations of zinc, copper, and iron. Biol Trace Elem Res 86:31–
44
328 Krośniak et al.
